# FLOT (5-FU, leucovorin, oxaliplatin, docetaxel) Source: https://onco.cc/drugs/flot/ OnCo record `flot` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence. ## TL;DR FLOT is the four-drug chemotherapy given before and after surgery for stomach cancer in the West; since 2025 immunotherapy is added to it. ## Summary FLOT4-AIO (2019): perioperative FLOT beat ECF/ECX (OS 50 vs 35 months). MATTERHORN added durvalumab (OS HR 0.78; FDA approval November 2025). Four cycles before and four after gastrectomy. Neutropenia, neuropathy, and diarrhoea; tolerability limits use in frail patients, where FOLFOX or CAPOX substitute. ## Fields - Kind: Treatment - Status: standard-of-care - Last checked: 2026-09-07 - Modality: Cytotoxic regimen - Mechanism: Docetaxel stabilises microtubules; oxaliplatin crosslinks DNA; 5-FU/leucovorin inhibit thymidylate synthase. - Dosing: Intravenous; Docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU 2,600 mg/m² over 24 h, every 14 days; 4 cycles pre- and 4 post-operative ## Sources - Wikipedia: https://en.wikipedia.org/wiki/FLOT - Wikipedia: https://en.wikipedia.org/wiki/FLOT ## Connected records - drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/) - cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Microsatellite-unstable (MSI-high) gastric cancer](https://onco.cc/cancers/gastric-msi-high/), [Oesophageal and junctional adenocarcinoma](https://onco.cc/cancers/oesophageal-adenocarcinoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [PD-L1-high gastric cancer](https://onco.cc/cancers/gastric-pdl1-high/) - technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/) - terms: [FLOT regimen (perioperative chemotherapy for gastric cancer)](https://onco.cc/terms/flot-term/), [Gastrectomy](https://onco.cc/terms/gastrectomy/), [Gastro-oesophageal junction (GEJ)](https://onco.cc/terms/gej/) - trials: [A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)](https://onco.cc/trials/nct06428409/), [A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer](https://onco.cc/trials/nct07474727/), [A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer](https://onco.cc/trials/nct05382442/), [A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer](https://onco.cc/trials/nct05379595/), [A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation](https://onco.cc/trials/nct07678593/), [A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer](https://onco.cc/trials/nct07805551/), [A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer](https://onco.cc/trials/nct06792695/), [A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based](https://onco.cc/trials/nct07803783/), [A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06598007/), [A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,](https://onco.cc/trials/nct06820463/), [A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ](https://onco.cc/trials/nct06948448/), [AK129 Combination Therapy for Advanced Solid Tumors](https://onco.cc/trials/nct06943820/), [AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2](https://onco.cc/trials/nct06219941/), [BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours](https://onco.cc/trials/nct04421820/), [FOG-001 in Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05919264/), [Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic C](https://onco.cc/trials/nct06897644/), [GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors](https://onco.cc/trials/nct04083599/), [Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)](https://onco.cc/trials/nct07432295/), [HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer](https://onco.cc/trials/nct07790510/), [Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pan](https://onco.cc/trials/nct07542002/), [MATTERHORN](https://onco.cc/trials/matterhorn/), [Newly Emerging Immunotherapy for Pancreatic Cancer Treatment](https://onco.cc/trials/nct06370754/), [PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment](https://onco.cc/trials/nct07028424/), [Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer](https://onco.cc/trials/nct07228832/), [SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial](https://onco.cc/trials/nct07748611/), [Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer](https://onco.cc/trials/nct06259058/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast](https://onco.cc/trials/nct07775287/), [Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06535607/), [Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta](https://onco.cc/trials/nct07621718/), [Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations](https://onco.cc/trials/nct06998940/), [Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers](https://onco.cc/trials/nct04430738/), [Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer](https://onco.cc/trials/nct03977233/) --- JSON: https://onco.cc/api/v1/entities/flot.json